Short Interest Summary: Combimatrix Corporation (NASDAQ:CBMX) Sellers Increased By 9.75% Their Shorts

November 28, 2016 - By Dolores Ford   ·   0 Comments

Short Interest Summary: Combimatrix Corporation (NASDAQ:CBMX) Sellers Increased By 9.75% Their Shorts

The stock of Combimatrix Corporation (NASDAQ:CBMX) registered an increase of 9.75% in short interest. CBMX’s total short interest was 241,900 shares in November as published by FINRA. Its up 9.75% from 220,400 shares, reported previously. With 35,800 shares average volume, it will take short sellers 7 days to cover their CBMX’s short positions. The short interest to Combimatrix Corporation’s float is 11.8%. About 26,816 shares traded hands. CombiMatrix Corp (NASDAQ:CBMX) has declined 9.68% since April 25, 2016 and is downtrending. It has underperformed by 15.69% the S&P500.

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The company has a market cap of $6.87 million. The Firm specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It currently has negative earnings. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping.

CBMX Company Profile

CombiMatrix Corporation, incorporated on July 11, 2000, is a well-known provider of molecular diagnostic solutions. The Firm specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid (DNA) testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. The Firm performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis (CMA), fluorescence in situ hybridization (FISH) and karyotyping. The Firm also holds interests in Leuchemix, Inc., which is a drug development firm focused on developing a series of compounds to address a number of oncology-related diseases. The Firm develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (also referred to as products of conception analysis (POC)), prenatal genetics and postnatal developmental disorders.

More important recent CombiMatrix Corp (NASDAQ:CBMX) news were published by: Marketwatch.com which released: “CombiMatrix’s stock soars 21% premarket after distribution agreement announced” on February 24, 2011, also Quotes.Wsj.com published article titled: “CombiMatrix Corp. CBMX (US: Nasdaq)”, Reuters.com published: “BRIEF-Combimatrix Corp reports Q3 loss per share $0.38” on November 02, 2016. More interesting news about CombiMatrix Corp (NASDAQ:CBMX) was released by: Streetinsider.com and their article: “Form 8-K CombiMatrix Corp For: Nov 02” with publication date: November 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Dolores Ford


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>